Sunshine Biopharma (NASDAQ:SBFM) Posts Quarterly Earnings Results, Misses Estimates By $1.80 EPS

Sunshine Biopharma (NASDAQ:SBFM) posted its earnings results on Thursday. The company reported ($5.20) earnings per share for the quarter, missing the consensus estimate of ($3.40) by ($1.80), FiscalAI reports. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The firm had revenue of $9.44 million for the quarter, compared to analysts’ expectations of $9.60 million.

Sunshine Biopharma Trading Down 2.6%

SBFM traded down $0.07 during trading on Friday, hitting $2.77. The company’s stock had a trading volume of 11,316 shares, compared to its average volume of 114,826. Sunshine Biopharma has a twelve month low of $2.53 and a twelve month high of $464.00. The business’s fifty day simple moving average is $10.44 and its 200 day simple moving average is $98.38. The firm has a market capitalization of $608,300.00, a price-to-earnings ratio of -0.01 and a beta of 1.32.

Analyst Ratings Changes

A number of analysts recently issued reports on SBFM shares. Weiss Ratings raised shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 28th. Wall Street Zen raised shares of Sunshine Biopharma to a “hold” rating in a report on Saturday, October 31st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

About Sunshine Biopharma

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.